Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net revenues	$ 494,366	$ 351,318	$ 248,069
Cost of revenues	106,501	88,606	80,048
Gross profit	387,865	262,712	168,021
Operating costs and expenses:
Research, development and clinical trials	132,010	79,003	50,574
Sales and marketing	118,017	96,675	77,663
General and administrative	107,437	87,948	73,456
Total operating costs and expenses	357,464	263,626	201,693
Operating income (loss)	30,401	(914)	(33,672)
Financial expenses (income), net	12,299	7,910	12,270
Income (loss) before income taxes	18,102	(8,824)	(45,942)
Income tax	(1,706)	(1,594)	17,617
Net income (loss)	$ 19,808	$ (7,230)	$ (63,559)
Basic net income (loss) per ordinary share (in usd per share)	$ 0.20	$ (0.07)	$ (0.69)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	100,930,866	97,237,549	91,828,043
Diluted net income (loss) per ordinary share (in usd per share)	$ 0.18	$ (0.07)	$ (0.69)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	108,877,648	97,237,549	91,828,043